The fate of chemoresistance in triple negative breast cancer (TNBC).

ABSTRACT:

Background

Treatment options for women presenting with triple negative breast cancer (TNBC) are limited due to the lack of a therapeutic target and as a result, are managed with standard chemotherapy such as paclitaxel (Taxol®). Following chemotherapy, the ideal tumour response is apoptotic cell death. Post-chemotherapy, cells can maintain viability by undergoing viable cellular responses such as cellular senescence, generating secretomes which can directly enhance the malignant phenotype.

Scope of review

How tumour cells retain viability in response to chemotherapeutic engagement is discussed. In addition we discuss the implications of this retained tumour cell viability in the context of the development of recurrent and metastatic TNBC disease. Current adjuvant and neo-adj

SUBMITTER: O'Reilly EA 

PROVIDER: S-EPMC4661576 | biostudies-literature | 2015 Jun

REPOSITORIES: biostudies-literature